Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Null Results in Brief

Steroid 5-α Reductase Type II V89L Substitution Is Not Associated with Risk of Prostate Cancer in a Multiethnic Population Study

Celeste L. Pearce, Nick M. Makridakis, Ronald K. Ross, Malcolm C. Pike, Laurence N. Kolonel, Brian E. Henderson and Juergen K. V. Reichardt
Celeste L. Pearce
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick M. Makridakis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald K. Ross
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malcolm C. Pike
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurence N. Kolonel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian E. Henderson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juergen K. V. Reichardt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Introduction

Although the genetic causes of prostate cancer are poorly understood, variation in androgen biosynthesis and metabolism genes has been hypothesized to alter prostate cancer risk (1) . Steroid 5-α reductase type II, which encodes the enzyme responsible for converting testosterone to dihydrotestosterone in the prostate, has been studied as a candidate gene (2, 3, 4) . A missense single nucleotide polymorphism at codon 89, resulting in a valine to leucine change (V89L), was tested in relation to prostate cancer risk in three previous case-control studies. A large nested case-control study within the Physicians’ Health Study found a small protective effect of the LL genotype that was not statistically significant (2) . Similarly, Lunn et al. (3) found a 10% reduction in risk associated with the LL genotype, but again this result did not achieve statistical significance. However, a recent case-control study suggested a much stronger effect of the V89L single nucleotide polymorphism; this study found a 64% decrease in risk associated with the LL genotype compared with the VV genotype (4) .

We report here the results of a large multiethnic case-control study designed to test the association between the V89L variant and prostate cancer risk.

Materials and Methods

We completed a case-control study nested in the Hawaii-Los Angeles MEC3 , including 921 incident cases and 1295 male controls from the four major racial/ethnic groups enrolled in the cohort (African-Americans, Japanese-Americans, Latinos, and whites). Details of the MEC have been published previously (5) . Incident case ascertainment was completed by computer linkage of the cohort with the Surveillance, Epidemiology and End Results cancer registries in Hawaii and Los Angeles, as well as with the California State Cancer Registry. Both incident prostate cancer cases and a random sample of male controls in the MEC were contacted by phone and asked to provide a blood specimen. The overall participation rate for blood collection was 72% for cases and 69% for controls.

The men who agreed to participate in the blood collection provided written informed consent after study approval by both the University of Hawaii and the University of Southern California Institutional Review Boards.

DNA was purified from lymphocytes of peripheral blood samples for all cases and controls using either a rapid DNA preparation or the Gentra PureGene kit. Genotyping was carried out as described previously (6) . All samples were submitted in coded format for genotyping and included 5% masked repeats. PSA levels were determined for all controls in the study.

Logistic regression was used to model the association between risk of prostate cancer and V89L genotype. No mode of inheritance was assumed. All analyses were adjusted for age at entry into the MEC and for ethnicity in any analysis that combined the four ethnic groups.

Results

We found no significant association between the V89L variant and prostate cancer risk in any individual ethnic group, nor in all groups combined (Table 1⇓ ). We found a small, nonsignificant protective association between the LL genotype and risk of prostate cancer in the Latino and white groups; however, risk was slightly increased among African-American and Japanese-American men (Table 1⇓ ), indicating no strong or consistent pattern across racial/ethnic groups. The results were unchanged when restricted to cases with advanced disease.

View this table:
  • View inline
  • View popup
Table 1

ORs and 95% CIs for the association between the V89L genotype and risk of prostate cancer by racial/ethnic group

Conclusions

The results presented here agree with two of the three previously published studies suggesting no substantial association between the V89L variant and risk of prostate cancer. The findings from the third study may be in disagreement attributable to chance. The participants in our study were not screened for prostate cancer as part of follow-up, and therefore it is possible that some controls could have undetected disease. The low PSA levels in our controls indicate that misclassification of participants because of undetected disease is not likely to explain our lack of significant findings, and our results are unchanged when excluding controls with PSA values of 4 or higher.

Our study had 80% power at the α = 0.05 level to detect an OR of 0.64, the risk observed in the previously published “positive” study. A formal meta-analysis of the four studies (including only the white group from our study) revealed a 20% decreased risk for carriers of the LL genotype compared with the VV genotype (95% CI, 0.59–1.09), but this result was not statistically significant. Although we cannot rule out a small effect of this missense substitution on prostate cancer risk, the sample size required to detect an OR of 0.80 is quite large (n = 8796). The usefulness of conducting a study powered to detect such a small effect is unclear because this variant would not contribute significantly to the public health burden of prostate cancer in terms of either screening or prevention. Efforts should be focused elsewhere to further our understanding of the role of genetic variation in risk of prostate cancer.

Acknowledgments

We thank Hanh Nguyen and Nhuc Luong for genotyping assistance.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 This work was supported by Grants R01 CA68581, R01 CA63464, R01 CA54281, and Cancer Center Core Grant 2 P30 CA14089-26.

  • ↵2 To whom requests for reprints should be addressed, at USC/Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Room 4425, Los Angeles, CA 90089-9176.

  • ↵3 The abbreviations used are: MEC, Multiethnic Cohort; PSA, prostate-specific antigen; OR, odds ratio; CI, confidence interval.

  • Received December 7, 2001.
  • Revision received December 7, 2001.
  • Accepted January 28, 2002.

References

  1. ↵
    Ross R. K., Pike M. C., Coetzee G. A., Reichardt J. K., Yu M. C., Feigelson H., Stanczyk F. Z., Kolonel L. N., Henderson B. E. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res., 58: 4497-4504, 1998.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Febbo P. G., Kantoff P. W., Platz E. A., Casey D., Batter S., Giovannucci E., Hennekens C. H., Stampfer M. J. The V89L polymorphism in the 5-α reductase type 2 gene and risk of prostate cancer. Cancer Res., 59: 5878-5881, 1999.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Lunn R., Bell D., Mohler J., Taylor J. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis (Lond.), 20: 1727-1731, 1999.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Nam R., Toi A., Vesprini D., Ho M., Chu W., Harvie S., Sweet J., Trachtenberg J., Jewett M., Narod S. V89L polymorphism of type-2,5-α reductase enzyme gene predicts prostate cancer presence and progression. Urology, 57: 199-205, 2001.
    OpenUrlCrossRefPubMed
  5. ↵
    Kolonel L., Henderson B., Hankin J., Nomura A., Wilkens L., Pike M., Stram D., Monroe K., Earle M. E., Nagamine F. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am. J. Epidemiol., 151: 346-357, 2000.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Makridakis N., Ross R. K., Pike M. C., Chang L., Stanczyk F. Z., Kolonel L. N., Shi C. Y., Yu M. C., Henderson B. E., Reichardt J. K. V. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res., 57: 1020-1022, 1997.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
April 2002
Volume 11, Issue 4
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Steroid 5-α Reductase Type II V89L Substitution Is Not Associated with Risk of Prostate Cancer in a Multiethnic Population Study
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Steroid 5-α Reductase Type II V89L Substitution Is Not Associated with Risk of Prostate Cancer in a Multiethnic Population Study
Celeste L. Pearce, Nick M. Makridakis, Ronald K. Ross, Malcolm C. Pike, Laurence N. Kolonel, Brian E. Henderson and Juergen K. V. Reichardt
Cancer Epidemiol Biomarkers Prev April 1 2002 (11) (4) 417-418;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Steroid 5-α Reductase Type II V89L Substitution Is Not Associated with Risk of Prostate Cancer in a Multiethnic Population Study
Celeste L. Pearce, Nick M. Makridakis, Ronald K. Ross, Malcolm C. Pike, Laurence N. Kolonel, Brian E. Henderson and Juergen K. V. Reichardt
Cancer Epidemiol Biomarkers Prev April 1 2002 (11) (4) 417-418;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Introduction
    • Materials and Methods
    • Results
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Associations of ACEi and ARB with CRC risk
  • PDE5 Inhibitor Use and Precursors of Colorectal Cancer
  • Association Between Serum Iron Biomarkers and Breast Cancer
Show more Null Results in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement